{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:50:12Z","timestamp":1771653012726,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fast initiation of ART has been associated with higher rates of retention in HIV care and viral suppression at 48\u2005weeks and with lower mortality rates. However, scarce evidence exists in our setting, where diagnosis and treatment are carried out in different contexts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An observational retrospective study evaluating efficacy and safety of ART prescribed at the first specialist appointment, without baseline laboratory data, in a tertiary hospital in downtown Madrid. Individuals with a new diagnosis of HIV infection who initiated treatment at their first appointment with an infectious diseases specialist before receiving baseline laboratory results were included, irrespective of the ART regimen chosen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and eight participants were included. The majority (99.1%) were MSM who had acquired infection during sexual intercourse. The efficacy of ART, without baseline laboratory results at the time of initiation, was 85.2% (92\/108) in the ITT analysis and 91.7% (99\/108) in the treatment-related discontinuation equals failure analysis. All but nine patients presented an undetectable viral load (&amp;lt;50\u2005copies\/mL) at 48\u2005weeks from starting ART. No serious adverse effects associated with the strategy were observed. In total, 101 participants continued care at 48\u2005weeks with retention in HIV care rate of 93.5% (101\/108).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Initiating ART at the first available opportunity without baseline laboratory data does not reduce efficacy or safety of ART and achieves rapid virological control with high rates of retention in HIV care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac079","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T12:07:23Z","timestamp":1646654843000},"page":"1741-1747","source":"Crossref","is-referenced-by-count":5,"title":["Initiation of antiretroviral therapy in treatment-naive adults with HIV infection at the first specialist appointment"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4648-7657","authenticated-orcid":false,"given":"Aws Waleed M.","family":"Al-Hayani","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-8358","authenticated-orcid":false,"given":"Alfonso","family":"Cabello-\u00dabeda","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Del Palacio-Tamarit","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Rodr\u00edguez-Alonso","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Carrillo-Acosta","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"\u00c1lvarez-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Prieto-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fern\u00e1ndez Quintela","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Fuensalida","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"T\u00e9llez","sequence":"additional","affiliation":[{"name":"Department of Immunology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, IIS-FJD, UAM , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Luis-Casta\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Immunology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, IIS-FJD, UAM , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Hern\u00e1ndez-Segurado","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, IIS-FJD, UAM , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Becares","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, IIS-FJD, UAM , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Miguel","family":"Benito","sequence":"additional","affiliation":[{"name":"HIV and Viral Hepatitis Research Laboratory, IIS-FJD, UAM , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma","family":"Rall\u00f3n","sequence":"additional","affiliation":[{"name":"HIV and Viral Hepatitis Research Laboratory, IIS-FJD, UAM , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"G\u00f3rgolas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"2022053122483175300_dkac079-B1","article-title":"Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy","author":"WHO"},{"key":"2022053122483175300_dkac079-B2","article-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents\u2014A Working Group of the Office of AIDS Research Advisory Council (OARAC). Department of Health and Human Services","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2022053122483175300_dkac079-B3","article-title":"Version 11.0, October 2021","author":"European AIDS Clinical Society Guidelines","year":"2019"},{"key":"2022053122483175300_dkac079-B4","article-title":"Documento de consenso de Ge SIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana","author":"Ram\u00f3n Arribas Rosa Polo","year":"2020"},{"key":"2022053122483175300_dkac079-B5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection","volume":"373","author":"INSIGHT START Study Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2022053122483175300_dkac079-B6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"key":"2022053122483175300_dkac079-B7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"2022053122483175300_dkac079-B8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/infdis\/jit311","article-title":"Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size","volume":"208","author":"Jain","year":"2013","journal-title":"J Infect Dis"},{"key":"2022053122483175300_dkac079-B9","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Articles Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"2022053122483175300_dkac079-B10","doi-asserted-by":"crossref","first-page":"e0236031","DOI":"10.1371\/journal.pone.0236032","article-title":"Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model","volume":"15","author":"Berenguer","year":"2020","journal-title":"PLoS One"},{"key":"2022053122483175300_dkac079-B11","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"2022053122483175300_dkac079-B12","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis","volume":"370","author":"Boulware","year":"2014","journal-title":"N Engl J Med"},{"key":"2022053122483175300_dkac079-B13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","article-title":"Benefits and risks of rapid initiation of antiretroviral therapy","volume":"32","author":"Ford","year":"2018","journal-title":"AIDS"},{"key":"2022053122483175300_dkac079-B14","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1093\/cid\/ciz1213","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: Primary analysis of the DIAMOND study","volume":"71","author":"Huhn","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022053122483175300_dkac079-B15","article-title":"Feasibility, efficacy, and safety of using dolutegravir\/lamivudine (DTG\/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): the STAT study. HIV Drug Therapy Glasgow, UK, 2020, Virtual Congress. Poster 020","author":"Rolle"},{"key":"2022053122483175300_dkac079-B16","article-title":"IMEA 055 FAST: Rapid BIC\/FTC\/TAF - Capsule Summary Slidesets - Highlights - EACS 2021 - HIV - Clinical Care Options"},{"key":"2022053122483175300_dkac079-B17","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3018(18)30132-2","article-title":"Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study","volume":"5","author":"Bavinton","year":"2018","journal-title":"Lancet HIV"},{"key":"2022053122483175300_dkac079-B18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0000000000002447","article-title":"Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection","volume":"34","author":"Veil","year":"2020","journal-title":"AIDS"},{"key":"2022053122483175300_dkac079-B19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/QAI.0000000000001134","article-title":"The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting","volume":"74","author":"Pilcher","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022053122483175300_dkac079-B20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jama.2018.1818","article-title":"Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: The CASCADE randomized clinical trial","volume":"319","author":"Labhardt","year":"2018","journal-title":"JAMA"},{"key":"2022053122483175300_dkac079-B21","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1016\/S2352-3018(16)30090-X","article-title":"Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial","volume":"3","author":"Amanyire","year":"2016","journal-title":"Lancet HIV"},{"key":"2022053122483175300_dkac079-B22","doi-asserted-by":"crossref","first-page":"e1002015","DOI":"10.1371\/journal.pmed.1002015","article-title":"Initiating antiretroviral therapy for HIV at a patient\u2019s first clinic visit: The RapIT randomized controlled trial","volume":"13","author":"Rosen","year":"2016","journal-title":"PLoS Med"},{"key":"2022053122483175300_dkac079-B23","doi-asserted-by":"crossref","first-page":"e1002357","DOI":"10.1371\/journal.pmed.1002357","article-title":"Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial","volume":"14","author":"Koenig","year":"2017","journal-title":"PLoS Med"},{"key":"2022053122483175300_dkac079-B24","article-title":"Association between time to ART and loss to care among newly diagnosed PLWH in Rwanda","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 2020","author":"Ross"},{"key":"2022053122483175300_dkac079-B25","doi-asserted-by":"crossref","first-page":"32947","DOI":"10.1038\/srep32947","article-title":"Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis","volume":"6","author":"Hoenigl","year":"2016","journal-title":"Sci Rep"},{"key":"2022053122483175300_dkac079-B26","doi-asserted-by":"crossref","first-page":"e13016","DOI":"10.1097\/MD.0000000000013016","article-title":"Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-na\u00efve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study","volume":"97","author":"Jacobson","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2022053122483175300_dkac079-B27","article-title":"Seizeng the momento. Tackling entrenched inequalities to end epidemics. Global AIDS Update 2020","author":"UNAIDS"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/6\/1741\/43893366\/dkac079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/6\/1741\/43893366\/dkac079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T22:50:47Z","timestamp":1654037447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/6\/1741\/6548622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac079","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,15]]}}}